[go: up one dir, main page]

TWI368523B - Pharmaceutical compositions comprising imatinib and a release retardant - Google Patents

Pharmaceutical compositions comprising imatinib and a release retardant

Info

Publication number
TWI368523B
TWI368523B TW095116437A TW95116437A TWI368523B TW I368523 B TWI368523 B TW I368523B TW 095116437 A TW095116437 A TW 095116437A TW 95116437 A TW95116437 A TW 95116437A TW I368523 B TWI368523 B TW I368523B
Authority
TW
Taiwan
Prior art keywords
imatinib
pharmaceutical compositions
release retardant
retardant
release
Prior art date
Application number
TW095116437A
Other languages
English (en)
Other versions
TW200716205A (en
Inventor
Madhav Vasanthavada
Jay Parthiban Lakshman
Wei-Qin Tong
Abu T M Serajuddin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI368523(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200716205A publication Critical patent/TW200716205A/zh
Application granted granted Critical
Publication of TWI368523B publication Critical patent/TWI368523B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/02—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/05—Filamentary, e.g. strands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/06—Rod-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
    • B29C48/395—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders
    • B29C48/40—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws or at least two parallel non-intermeshing screws, e.g. twin screw extruders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/88—Thermal treatment of the stream of extruded material, e.g. cooling
    • B29C48/911—Cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2001/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
    • B29K2001/08—Cellulose derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25—Solid
    • B29K2105/251—Particles, powder or granules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0056—Biocompatible, e.g. biopolymers or bioelastomers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0059—Degradable
    • B29K2995/006—Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
TW095116437A 2005-05-10 2006-05-09 Pharmaceutical compositions comprising imatinib and a release retardant TWI368523B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67960705P 2005-05-10 2005-05-10

Publications (2)

Publication Number Publication Date
TW200716205A TW200716205A (en) 2007-05-01
TWI368523B true TWI368523B (en) 2012-07-21

Family

ID=37027884

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095116437A TWI368523B (en) 2005-05-10 2006-05-09 Pharmaceutical compositions comprising imatinib and a release retardant

Country Status (32)

Country Link
US (2) US20080226731A1 (zh)
EP (1) EP1888040B1 (zh)
JP (1) JP5054000B2 (zh)
KR (2) KR20080007249A (zh)
CN (1) CN101175483B (zh)
AR (1) AR054114A1 (zh)
AT (1) ATE477794T1 (zh)
AU (1) AU2006244359B2 (zh)
BR (1) BRPI0608605A2 (zh)
CA (1) CA2606602C (zh)
CY (1) CY1111389T1 (zh)
DE (1) DE602006016270D1 (zh)
DK (1) DK1888040T3 (zh)
ES (1) ES2350002T3 (zh)
GT (1) GT200600194A (zh)
HR (1) HRP20100615T1 (zh)
IL (1) IL186925A (zh)
JO (1) JO2647B1 (zh)
MA (1) MA29463B1 (zh)
MX (1) MX2007014067A (zh)
MY (1) MY148074A (zh)
NO (1) NO20076288L (zh)
NZ (1) NZ562538A (zh)
PE (1) PE20061449A1 (zh)
PL (1) PL1888040T3 (zh)
PT (1) PT1888040E (zh)
RU (1) RU2404775C2 (zh)
SA (1) SA06270134B1 (zh)
TN (1) TNSN07417A1 (zh)
TW (1) TWI368523B (zh)
WO (1) WO2006121941A2 (zh)
ZA (1) ZA200708839B (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004233898B2 (en) 2003-04-25 2010-12-23 Gilead Sciences, Inc. Antiviral phosphonate analogs
ES2363160T3 (es) 2004-07-27 2011-07-22 Gilead Sciences, Inc. Conjugados de fosfonato nucelosidico como agentes anti-vih.
ATE445392T1 (de) * 2005-08-15 2009-10-15 Siegfried Generics Int Ag Filmtablette oder granulat enthaltend ein pyridylpyrimidin
AU2007299764B2 (en) 2006-09-22 2011-10-13 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with Abl tyrosine kinase inhibitors
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
EP2120877A2 (en) * 2007-03-12 2009-11-25 Dr. Reddy's Laboratories Ltd. Imatinib mesylate
DK2305263T3 (da) * 2007-06-07 2012-10-22 Novartis Ag Stabiliserede amorfe former af imatinibmesylat
AU2012201613B2 (en) * 2007-06-07 2014-12-04 Novartis Ag Stabilized amorphous forms of Imatinib mesylate
EP2191848A4 (en) * 2007-08-31 2013-05-15 Daiichi Sankyo Co Ltd PREPARATION WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF
EP2081556A1 (en) 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
CN101951910B (zh) 2008-01-23 2013-07-17 诺瓦提斯公司 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2268265A2 (en) * 2008-03-21 2011-01-05 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
JP2012510470A (ja) 2008-12-01 2012-05-10 ノバルティス アーゲー メシル酸イマチニブを用いたフィラデルフィア陽性白血病の処置を最適化する方法
CA2789307A1 (en) * 2010-03-29 2011-10-06 Hetero Research Foundation Stable pharmaceutical composition of imatinib
WO2011161689A1 (en) * 2010-06-21 2011-12-29 Suven Nishtaa Pharma Pvt Ltd Imatinib mesilate pharmaceutical tablet
MX2013001653A (es) 2010-08-11 2013-05-22 Synthon Bv Granulado farmaceutico que comprende mesilato de imatinib
WO2012080703A1 (en) 2010-12-15 2012-06-21 Cipla Limited Pharmaceutical composition comprising imatinib
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) * 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2013008253A2 (en) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Imatinib formulations
JP6086520B2 (ja) * 2011-08-22 2017-03-01 大原薬品工業株式会社 薬物高含有固形製剤
US20150125534A1 (en) 2011-11-24 2015-05-07 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Imatinib solid dosage forms reconstituted just before use
KR101428149B1 (ko) * 2011-12-23 2014-08-08 씨제이헬스케어 주식회사 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
US9757465B2 (en) * 2012-04-11 2017-09-12 Dow Global Technologies Llc Composition comprising an organic diluent and a cellulose ether
WO2013154977A1 (en) * 2012-04-11 2013-10-17 Dow Global Technologies Llc Novel sustained release dosage forms
BR112014020718B1 (pt) * 2012-04-11 2020-11-17 Dow Global Technologies Llc composição polimérica extrusada sob fusão, processo para produzir uma composição polimérica extrusada sob fusão e uso de pelo menos um éter de celulose
RU2517216C2 (ru) * 2012-08-22 2014-05-27 Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД") Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
US9956709B2 (en) 2013-05-27 2018-05-01 Steerlife India Private Limited Hot melt fragmentation extruder and process
WO2015004556A1 (en) * 2013-07-09 2015-01-15 Shilpa Medicare Limited Oral pharmaceutical compositions comprising imatinib mesylate
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
CN104146973B (zh) * 2014-08-14 2017-09-05 杭州华东医药集团新药研究院有限公司 一种含有甲磺酸伊马替尼组合物及其制备方法
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
SE539450C2 (en) 2016-02-29 2017-09-26 Imatinib for use in the treatment of stroke
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
EA033102B1 (ru) * 2017-08-21 2019-08-30 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция с модифицированным отсроченным и длительным высвобождением, содержащая аспарагинаты
AU2020312840A1 (en) * 2019-07-15 2022-01-20 Intas Pharmaceuticals Ltd. Pharmaceutical composition of imatinib
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
ES2358319T3 (es) * 2001-02-27 2011-05-09 Senju Pharmaceutical Co., Ltd. Sistema de liberación de fármaco del tipo polímero biodegradable.
DE10207586A1 (de) 2002-02-22 2003-09-11 Degussa Herstellung von N-Methyl-3-hydroxy-3-(2-thienyl)propanamin über neue carbamatgruppenhaltige Thiophenderivate als Zwischenprodukte
ATE339197T1 (de) * 2002-03-15 2006-10-15 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2490989A1 (en) * 2002-05-13 2003-11-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof

Also Published As

Publication number Publication date
NZ562538A (en) 2011-03-31
IL186925A0 (en) 2008-02-09
JP5054000B2 (ja) 2012-10-24
AU2006244359A1 (en) 2006-11-16
US20080226731A1 (en) 2008-09-18
JO2647B1 (en) 2012-06-17
HRP20100615T1 (hr) 2010-12-31
CY1111389T1 (el) 2015-08-05
CN101175483A (zh) 2008-05-07
DE602006016270D1 (de) 2010-09-30
MX2007014067A (es) 2008-02-07
CN101175483B (zh) 2012-06-20
JP2008540531A (ja) 2008-11-20
HK1116067A1 (zh) 2008-12-19
ES2350002T3 (es) 2011-01-14
PL1888040T3 (pl) 2011-02-28
GT200600194A (es) 2006-12-04
MA29463B1 (fr) 2008-05-02
NO20076288L (no) 2008-02-05
AR054114A1 (es) 2007-06-06
IL186925A (en) 2011-11-30
PT1888040E (pt) 2010-10-28
DK1888040T3 (da) 2010-11-15
CA2606602A1 (en) 2006-11-16
EP1888040A2 (en) 2008-02-20
TNSN07417A1 (en) 2009-03-17
EP1888040B1 (en) 2010-08-18
ZA200708839B (en) 2008-11-26
KR20080007249A (ko) 2008-01-17
BRPI0608605A2 (pt) 2010-01-19
WO2006121941A2 (en) 2006-11-16
RU2404775C2 (ru) 2010-11-27
KR20100044286A (ko) 2010-04-29
ATE477794T1 (de) 2010-09-15
CA2606602C (en) 2013-08-27
US20140350027A1 (en) 2014-11-27
AU2006244359B2 (en) 2010-12-09
TW200716205A (en) 2007-05-01
WO2006121941A3 (en) 2007-01-11
SA06270134B1 (ar) 2009-02-07
RU2007145507A (ru) 2009-06-20
PE20061449A1 (es) 2007-01-20
KR101156916B1 (ko) 2012-06-21
MY148074A (en) 2013-02-28

Similar Documents

Publication Publication Date Title
TWI368523B (en) Pharmaceutical compositions comprising imatinib and a release retardant
EP1945197A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING A BETA ADRENE RECEPTOR ANTAGONIST WITH EXTENDED RELEASE
IL188964A0 (en) Sustained drug release composition
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP1765283A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA200705530B (en) Sustained release pharmaceutical formulations
GB0409703D0 (en) Pharmaceutical compositions
ZA200802947B (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
GB0408308D0 (en) Pharmaceutical compositions
IL188352A0 (en) Pharmaceutical compositions
ZA200804103B (en) Pharmaceutical compositions
EP1885665A4 (en) FORMULATIONS OF DITHIOCARBAMATES AND PHOSPHITE
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
IL192091A0 (en) Pharmaceutical compositions
IL186337A0 (en) Stannsoporfin compositions and administration
ZA200709692B (en) Antineoplastic compounds and pharmaceutical compositions thereof
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0522045D0 (en) Pharmaceutical compositions
EP1871348A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE
SI1888040T1 (sl) Farmacevtski sestavki, ki obsegajo imatinib in sredstvo za upočasnitev sproščanja
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0407351D0 (en) Pharmaceutical compositions
EP1865777A4 (en) STANNSOPORFIN COMPOSITIONS AND ADMINISTRATION
GB0400971D0 (en) Pharmaceutical compositions
ZA200803566B (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees